.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,017,965

« Back to Dashboard

Details for Patent: 6,017,965

Title: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Abstract:Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
Inventor(s): Mueller; Alan L. (Salt Lake City, UT), Balandrin; Manuel F. (Sandy, UT), VanWagenen; Bradford C. (Salt Lake City, UT), Moe; Scott T. (Salt Lake City, UT), DelMar; Eric G. (Salt Lake City, UT), Artman; Linda D. (Salt Lake City, UT), Barmore; Robert M. (Salt Lake City, UT), Smith; Daryl L. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT)
Filing Date:Dec 11, 1996
Application Number:08/763,480
Claims:1. A compound of the formula: ##STR353## wherein: X is independently selected from the group consisting of, --Br, --Cl, --F, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, and --O-acyl;

R.sub.1 is independently selected from the group consisting of --H, lower alkyl, and --O-acyl;

R.sub.2 is independently selected from the group consisting of --H, alkyl, and hydroxyalkyl, or both R.sub.2 s together are imino;

R.sub.4 is phenoxy which is optionally substituted with --F, --Cl, --Br, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3 --O-alkyl, or --O-acyl;

provided that when X is H, then R.sub.4 is substituted with meta-fluoro, meta-chloro, ortho-methyl, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and

m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.

2. A compound of the formula: ##STR354## wherein: X is independently selected from the group consisting of, --Br, --Cl, --F, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, and --O-acyl;

R.sub.1 is independently selected from the group consisting of --H, lower alkyl, and --O-acyl;

R.sub.2 is independently selected from the group consisting of --H, alkyl, and hydroxyalkyl, or both R.sub.2 s together are imino;

R.sub.4 is phenoxy which is optionally substituted with --F, --Cl, --Br, --I, --CF.sub.3 alkyl, --OH, --OCF.sub.3 --O-alkyl, or --O-acyl;

provided that when X is H, then R.sub.4 is substituted with meta-fluoro, meta-chloro, ortho-fluoro, ortho-chloro, meta-methyl, ortho-OH, or meta-OH; and

m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.

3. A compound of the formula: ##STR355## wherein: X is independently selected from the group consisting of --F, --Cl, --Br, --I, --CF.sub.3 alkyl, --OH, --OCF.sub.3, --O-alkyl, and --O-acyl;

R.sub.1 is independently selected from the group consisting of lower alkyl, and --O-acyl;

R.sub.2 is independently selected from the group consisting of --H, lower alkyl, and hydroxyalkyl, or both R.sub.2 s together are imino;

R.sub.3 is selected from the group consisting of methyl and ethyl;

R.sub.4 is phenoxy which is optionally substituted with --F, --Cl, --Br, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, or --O-acyl;

provided that when X is para-fluoro, R.sub.4 is not meta-CF.sub.3 -substituted phenoxy; and m is independently an integer from 1 to 5; and pharmaceutically acceptable salts and complexes thereof.

4. A compound of the formula: ##STR356## wherein: (X)m is selected from the group consisting of meta-fluoro, meta-chloro, ortho-O-lower alkyl, ortho-methyl, ortho-fluoro, ortho-chloro, meta-O-lower alkyl, meta-methyl, ortho-OH, and meta-OH;

R.sub.1 is H;

R.sub.2 is H;

R.sub.3 is selected from the group consisting of methyl and ethyl;

R.sub.4 is phenoxy which is optionally substituted with --F, --Cl, --Br, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, or --O-acyl; and pharmaceutically acceptable salts and complexes thereof.

5. A compound of the formula: ##STR357## wherein: X is independently selected from the group consisting of --H, --Br, --Cl, --F, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, and --O-acyl;

R.sub.1 is independently selected from the group consisting of --H, alkyl, hydroxyalkyl, --OH, --O-alkyl, and --O-acyl;

R.sub.2 is independently selected from the group consisting of --H, alkl, and hydroxyalkyl, or both R.sub.2 s together are imino;

R.sub.3 is independently selected from the group consisting of --H, methyl, and ethyl;

R.sub.4 is phenylthio which is optionally substituted with --F, --Cl, --Br, --I, --CF.sub.3, alkyl, --OH, --OCF.sub.3, --O-alkyl, or --O-acyl; and

m is independently an integer from 0 to 5; and pharmaceutically acceptable salts and complexes thereof.

6. A compound selected from the group consisting of ##STR358## and pharmaceutically acceptable salts and complexes thereof.

7. The compound of claim 6, selected from the group consisting of ##STR359##

8. The compound of claim 6, selected from the group consisting of

9. A compound having the chemical structure: and pharmaceutically acceptable salts and complexes thereof.

10. A compound having the chemical structure: ##STR360## and pharmaceutically acceptable salts and complexes thereof.

11. A compound having the chemical structure: ##STR361## and pharmaceutically acceptable salts and complexes thereof.

12. A compound having the chemical structure: ##STR362## and pharmaceutically acceptable salts and complexes thereof.

13. A pharmaceutical composition, comprising a compound as in any of claims 1-5 or 8-11, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition, comprising a compound of claim 6, and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition is adapted for the treatment of a neurological disease or disorder.

16. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition is adapted to provide neuroprotection to a patient.

17. The pharmaceutical composition of claim 14, wherein said compound is a hydrochloride salt.

18. The pharmaceutical composition of claim 15, wherein said compound is a hydrochloride salt.

19. The pharmaceutical composition of claim 16, wherein said compound is a hydrochloride salt.

20. A method for treating a patient having a neurological disease or disorder, comprising administering a compound as in any of claims 1-5 or 7-12.

21. A method for treating a patient having a neurological disease or disorder, comprising administering a compound as in claim 6.

22. The method of claim 21, wherein said neurological disease or disorder is selected from the group consisting of stroke, head trauma, spinal cord injury, epilepsy, anxiety, Alzheimer's disease, Huntington's disease, Parkinson's disease, and arnyotrophic lateral sclerosis.

23. The method of claim 22, wherein said neurological disease or disorder is stroke.

24. The method of claim 22, wherein said neurological disease or disorder is head trauma.

25. The method of claim 22, wherein said neurological disease or disorder is spinal cord injury.

26. The method of claim 22, wherein said neurological disease or disorder is epilepsy.

27. The method of claim 22, wherein said neurological disease or disorder is anxiety.

28. The method of claim 22, wherein said neurological disease or disorder is Alzheimer's disease.

29. The method of claim 22, wherein said neurological disease or disorder is Huntington's disease.

30. The method of claim 22, wherein said neurological disease or disorder is Parkinson's disease.

31. The method of claim 22, wherein said neurological disease or disorder is amyotrophic lateral sclerosis.

32. The method of claim 23, wherein said stroke is global ischemic.

33. The method of claim 23, wherein said stroke is hemorrhagic.

34. The method of claim 23, wherein said stroke is focal ischemic.

35. A method for providing neuroprotection to a patient, comprising administering a compound as in any of claims 1-8.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc